A locally-adapted economic model is necessary for aligning the economic and clinical benefits of your product with local therapy traditions and financing models. It is a must if Nordic HTA authorities are to make a positive decision regarding the reimbursement of your product.
When it comes to taking a pharmacautical product to the market, no two countries are alike.
Economic model adaptations to local context are necessary for aligning the messaging around your product with local clinical practice as well as economic landscape to the relevant decision maker.
We adapt global economic models to local conditions, taking into account variables such as:
-Healthcare costs
-Required perspective (e.g. societal or healthcare-related)
-Demographics
-Disease epidemiology
-Competitor products
-Local clinical practice etc.
We adapt cost-benefit models, cost-effectiveness models, cost-minimization models and budget impact models in order to present important outcomes such as Incremental Cost-effectiveness Ratio (ICER) and Quality Adjusted Life Year (QALY) aligned with local conditions.
Reimbursement dossier development
Payer value proposition development
Susanne Schuurman
Arex Advisor AB
Contact us
Staffan Thunell
Founding partner
BSc Economics and BA
Staffan has a long background in entrepreneurship within the life science industry. He has 20+ years experience from positions as Founder, Chairman, CEO and CFO within medical affairs consulting and small pharma. Previously Staffan worked in executive positions in big pharma and specialty pharma companies.